Pancreatic cancer develops when pancreas starts developing abnormally. Pancreatic cancer is categorized into two different types, which includes exocrine pancreatic cancer and endocrine pancreatic cancer. Tobacco use, obesity, chemical exposure, family history, diabetes, chronic pancreatitis, liver cirrhosis and inherited genetic syndromes are the risk factors associated with pancreatic cancer. According to American Cancer Society, pancreatic cancer accounts for about 3% of all the cancers in the U.S., and about 7% of all cancer deaths in the U.S. Pancreatic cancer can be treated by radiation therapy, chemotherapy and surgery. Erytech Pharma is in the process of developing eryaspase, as an asparagine modulator for the treatment of pancreatic cancer. Some of the companies having a pipeline of pancreatic cancer include Erytech Pharma, Biomunex Pharmaceuticals, Ipsen Group and others.
The report provides a comprehensive understanding of the pipeline activities covering all the drug candidates under the various stages of development. This report provides a global outline about the therapeutics pipeline of the disease, with detailed analysis of pipeline and clinical trials. The pipeline analysis of drugs by phases, includes information related to product description and other development activities, such as information with respect to designations, collaborations, licensing, grants, funding, and technology.